Caribou Bio receives RMAT and Fast Track designations from FDA for CB-010 CAR-T therapy

Caribou Biosciences, Inc.

FDA grants RMAT for relapsed/refractory large B cell lymphoma (LBCL) and Fast Track for r/r B-NHL for CB-010.
CB-010 is first allogeneic anti-CD19 CAR-T with PD-1 knockout in clinic.
In ANTLER Phase 1 trial at dose level 1: 6/6 patients (100%) achieved CR, 3/6 (50%) maintained CR at 6 months.
Designations offer expedited development benefits: Priority Review, Rolling Review, Accelerated Approval eligibility.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.